ARTHQ (Arch Therapeutics) Cyclically Adjusted PB Ratio: (As of Jul. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ARTHQ Arch Therapeutics Inc ARTHQ
12 GF Score
Price $0.00
View Full Analysis

What is Arch Therapeutics Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Arch Therapeutics  (OTCPK:ARTHQ) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Arch Therapeutics Cyclically Adjusted PB Ratio Related Terms


Arch Therapeutics Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Arch Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arch Therapeutics Cyclically Adjusted PB Ratio Chart

Arch Therapeutics Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Arch Therapeutics Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ARTHQ vs GRTSQ, MTEM, PXMD: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Arch Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arch Therapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arch Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Arch Therapeutics's Cyclically Adjusted PB Ratio falls into.


ARTHQ
12GF Score
Arch Therapeutics Inc ARTHQ
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Arch Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Arch Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2024 is calculated as:

For example, Arch Therapeutics's adjusted Book Value per Share data for the three months ended in Jun. 2024 was:

Adj_Book=Book Value per Share/CPI of Jun. 2024 (Change)*Current CPI (Jun. 2024)
=-2.827/314.1750*314.1750
=-2.827

Current CPI (Jun. 2024) = 314.1750.

Arch Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201409 -19.144 238.031 -25.268
201412 -14.279 234.812 -19.105
201503 -15.603 236.119 -20.761
201506 -13.071 238.638 -17.208
201509 2.862 237.945 3.779
201512 1.667 236.525 2.214
201603 0.214 238.132 0.282
201606 5.932 241.018 7.733
201609 4.628 241.428 6.023
201612 3.606 241.432 4.692
201703 6.077 243.801 7.831
201706 4.488 244.955 5.756
201709 2.900 246.819 3.691
201712 4.044 246.524 5.154
201803 2.695 249.554 3.393
201806 2.923 251.989 3.644
201809 1.655 252.439 2.060
201812 -0.805 251.233 -1.007
201903 -0.244 254.202 -0.302
201906 -0.198 256.143 -0.243
201909 -0.930 256.759 -1.138
201912 -0.108 256.974 -0.132
202003 -0.571 258.115 -0.695
202006 -0.330 257.797 -0.402
202009 -1.554 260.280 -1.876
202012 -2.662 260.474 -3.211
202103 1.733 264.877 2.056
202106 0.520 271.696 0.601
202109 -0.867 274.310 -0.993
202112 -2.046 278.802 -2.306
202203 -2.581 287.504 -2.820
202206 -3.388 296.311 -3.592
202209 -3.354 296.808 -3.550
202212 -4.715 296.797 -4.991
202303 -5.009 301.836 -5.214
202306 -6.237 305.109 -6.422
202309 -1.601 307.789 -1.634
202312 -2.019 306.746 -2.068
202403 -2.448 312.332 -2.462
202406 -2.827 314.175 -2.827

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Arch Therapeutics Business Description

Address 235 Walnut Street, Suite 6, Framingham, MA, USA, 01702
Arch Therapeutics Inc is a development-stage biotechnology company. It focuses on developing products that manage surgery and interventional care faster and safer by using a novel approach to stop bleeding, control leaking, and provide other advantages during surgery and trauma care. The company's primary product candidate, collectively known as the AC5 Devices (AC5), is designed to achieve hemostasis in surgical procedures. The company operates its business operations in the United States.
12GF Score

Get the complete analysis for ARTHQ

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price